Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2024-518215-18-00 | EU Trial (CTIS) Number | ||
| 2019-002251-42 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Sanofi | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
The goal of this clinical trial is to study the efficacy and safety of treatment with avalglucosidase alfa in patients with late onset Pompe disease that previously deteriorated on alglucosidase alfa.
The main question it aims to answer is:
Participants will switch to biweekly avalglucosidase alfa infusions (instead of alglucosidase alfa infusions) and perform assessment for:
Rationale: Not all patients with non-classic Pompe disease have a good response to current treatment with alglucosidase alfa. Therefore innovative enzyme replacement therapies are developed. The study drug avalglucosidase alfa has been tested in multiple clinical studies and will now be studied in a small population of patients that are unresponsive to alglucosidase alfa.
Objective: To explore safety, tolerability and efficacy of avalglucosidase alfa in patients with non-classic Pompe disease aged ≥ 5 years of whom clinical condition deteriorates while on standard treatment with alglucosidase alfa.
Study design: Single-center, open-label, repeated bi-weekly intravenous infusion study of avalglucosidase alfa in patients with non-classic Pompe disease patients aged ≥ 5 years, previously treated with alglucosidase alfa.
Study population: Non-classic Pompe disease patients aged ≥ 5 years and ≤ 55 years previously treated ≥ 2 years with alglucosidase alfa, who deteriorate despite treatment with alglucosidase alfa at a dose of 20 or 40 mg/kg bi-weekly.
Total number of patients = 6.
Intervention: Avalglucosidase alfa. Sterile lyophilized powder administered by intravenous infusion following reconstitution and dilution. 20 mg/kg bi-weekly
Main study parameters:
Safety
Pharmacokinetics
• Single and multiple dose estimates for Cmax, AUC, CL,.
Efficacy
Nature and extent of burden and risks associated with participation, benefit and group relatedness: Blood samples will be collected at 14 time points, the amount of blood will not exceed the maximum amount of 5 ML/kg over a period of 8 weeks. Patients will visit the hospital every other week to receive treatment. This treatment will last 4-6 hours. During every visit the vital signs of the patients will be checked and a physical examination is performed.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| avalglucosidase alfa treatment | Other | Treatment with avalglucosidase alfa, 20 mg/kg/every other week for a period of 5 years. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Avalglucosidase Alfa | Drug | Enzyme replacement therapy |
|
| Measure | Description | Time Frame |
|---|---|---|
| Incidence/occurrence of adverse events | Assessment of the occurrence/number of adverse events / treatment-emergent adverse events, including infusion associated reactions (IARs). Adverse events are scored using the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. | From enrollment to the end of study duration at 5 years |
| The occurence of antibodies against avalglucosidase alfa | The titer of antibodies against avalglucosidase alfa, scored as either no to low antibodies (< 1:1,250), intermediate (1:1,250 to < 1:31,250), or high (≥ 1:31,250). | From enrollment to the end of study duration at 5 years |
| Clinical laboratory evaluations aimed at liver and muscle function. | Values of ASAT, ALAT and CK (measured in U/L) as markers for muscle and liver function. | From enrollment to the end of study duration at 5 years |
| Changes in muscle strength using manual muscle testing (MMT) | Manual muscle testing (MMT) is performed using the Medical Research Council (MRC) grading scale. Muscle strength is graded from 0-5 by physical examination, in which grade 5 represents normal muscle strength and grade 0 means paralysis of the muscle group tested. | From enrollment to the end of study duration at 5 years |
| Changes in muscle strength using hand-held dynamometry (HHD) | Muscle strength will also be measured with the Cytec handheld dynamometer (HHD). A mean value in Newton is calculated from three consecutive measurements per muscle group. | From enrollment to the end of study duration at 5 years |
| Changes in muscle function using Quick Motor Function Test (QMFT) |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in vital signs using heart rate | Heart rate in beats per minute (bpm), scored prior to infusion, with each change in infusion rate and at the end of infusion. | From enrollment to the end of study duration at 5 years |
| Changes in vital signs using blood pressure |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Nadine van der Beek, MD PHD | Erasmus Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Erasmus MC | Rotterdam | 3015 GD | Netherlands |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
6 patients with late onset Pompe disease will be treated
Not provided
Not provided
Not provided
Not provided
For the quick motor function test, the patient is asked to perform several activities in supine, sitting and standing position, the performance of the patient is scored on a 5-point ordinal scale (range 0-4). A sumscore is calculated based on the maximum total score. |
| From enrollment to the end of study duration at 5 years |
| Changes in muscle function using the 6-Minute Walk Test (6-MWT) | The 6MWT is a timed test that measures functional endurance. The primary measurement is the distance walked in 6 minutes, measured in meters. The percent of predicted distance and the amount of time walked (to quantify endurance, as not all patients may complete the full 6-minute walk) will also be recorded. Eventual score is reported as a distance in meters (m) and a percent of the predicted score using the 1000 norms reference values. | From enrollment to the end of study duration at 5 years |
| Changes in muscle function using timed tests | Four timed tests will be performed to evaluate the impact of muscle weakness on the ability to perform functional activities of daily living. These timed tests include walking 10 meters, climbing four stairs, getting up from a supine position on the floor, and standing up from a chair. The number of seconds required to perform each activity will be noted. | From enrollment to the end of study duration at 5 years |
| Changes in pulmonary function using forced vital capacity (FVC) | Forced vital capacity in sitting and supine position will be measured and reported as percentage of predicted values, using the GLI 2012 reference values. | From enrollment to the end of study duration at 5 years |
| Changes in pulmonary function using Maximum Inspiratory Pressure (MIP) and Maximum Expiratory Pressure (MEP) | Both MIP and MEP are measured in kPa and then converted to a percentage of predicted values based on reference values. | From enrollment to the end of study duration at 5 years |
| Changes in patient reported outcome (PRO) measures using the Rasch-built Pompe-specific Activity scale (R-PAct) | The Rasch-Built Pompe-specific activity scale (R-PAct) will be performed in all patients who are ≥16 years at baseline. The R-PAct scale is a self-reported, 18-items questionnaire designed specifically for use in patients with Pompe disease, based upon experiences from patients about their most important and limiting aspects in daily life. All items have three response options: [0] unable to perform; [1] able to perform, but with difficulty or [2] able to perform without difficulty. If all items are answered, an appropriate centile metric score (range 0-100) will be calculated. | From enrollment to the end of study duration at 5 years |
| Changes in patient reported outcome (PRO) measures using the 36-Item Short Form Health Survey (SF-36) | The SF-36 is a health-related quality of life questionnaire, consisting of 36 items. The items are assigned to the domains of physical functioning, role functioning-physical, role functioning- emotional, social functioning, body pain, mental health, vitality, general health perception and change in health. The questionnaire will be used only for patients aged 16 years and older. A sumscore will be calculated based on the score on each item, and converted to a percentage of predicted score based on Dutch norm-based values. | From enrollment to the end of study duration at 5 years |
| Changes in patient reported outcome (PRO) measures using the TNO-AZL Child Quality of Life Questionnaire) | The TACQOL (TNO-AZL Child Quality of Life Questionnaire) is a generic instrument that measures quality of life in children aged 6-15 years. The questionnaire includes items representing the following concepts: physical complaints, motor functioning, autonomous functioning, social functioning, cognitive functioning, positive moods, and negative moods. For each of these scales, a scale score is calculated, where a higher score corresponds with a better quality of life. | From enrollment to the end of study duration at 5 years |
| Changes in patient reported outcome (PRO) measures using the modified Borg scale | The modified Borg scale is a patient-reported scale, derived from the original Borg scale, which is used to assess the subjective sensation of dyspnea of a patient. It is quantified from 0 to 10, in which 0 represents no symptoms (i.e. no dyspnea/shortness of breath) and 10 represents maximum symptoms. | From enrollment to the end of study duration at 5 years |
| Pharmacokinetics of avalglucocidase alfa | Single and multiple dose estimates for Cmax (in µg/mL), AUC (in μg∙hr/ml) and CL (in L/h), measured at two separate avalglucosidase alfa infusions (at baseline and 52 weeks). | From enrollment up to 1 year of study duration. |
Systolic and diastolic blood pressure in mmHg, scored prior to infusion, with each change in infusion rate and at the end of infusion. |
| From enrollment to the end of study duration at 5 years |
| Changes in vital signs using respiratory rate | Respiratory rate measured in number of breaths per minute, scored prior to infusion, with each change in infusion rate and at the end of infusion | From enrollment to the end of study duration at 5 years |
| Changes or abnormalities of cardiac function measured by electrocardiogram (ECG) | A standard 12-lead electrocardiogram (ECG) will be performed using an electrocardiographic device. The following variables will be assessed: heart rate (beats per minute), rhythm (type), interval from start of the Q wave to the end of the S wave (QRS) in milliseconds (ms), interval between the peaks of successive QRS complexes (RR) in ms, interval from the beginning of the P wave until the beginning of the QRS complex (PR) in ms, interval between the start of the Q wave and the end of the T wave (QT) in ms, QT interval corrected for heart rate (QTc) automatic correction evaluation (by the ECG device) in ms, QRS axis (direction), presence of left ventricular hypertrophy criteria, presence right ventricular hypertrophy criteria, and presence of repolarization charges (yes/no). These measurements will be aggregated to arrive at one reported outcome measure: abnormal ECG (Yes/No). Abnormal ECG is defined as an abnormality in any of the measurements mentioned above. | From enrollment to the end of study duration at 5 years |
| Assessment of use of ventilator | At each visit use of mechanical ventilation will be assessed, including the hours of ventilation per day - if applicable. | From enrollment to the end of study duration at 5 years |
| ID | Term |
|---|---|
| D006009 | Glycogen Storage Disease Type II |
| ID | Term |
|---|---|
| D020140 | Lysosomal Storage Diseases, Nervous System |
| D020739 | Brain Diseases, Metabolic, Inborn |
| D001928 | Brain Diseases, Metabolic |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D008661 | Metabolism, Inborn Errors |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D006008 | Glycogen Storage Disease |
| D002239 | Carbohydrate Metabolism, Inborn Errors |
| D016464 | Lysosomal Storage Diseases |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided